Compare Teradyne, Inc. (TER) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs TG Therapeutics Inc — how do they compare? Teradyne, Inc. trades at $379.74 (market cap $59.99B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: Teradyne, Inc. is far larger — about 7.2× TG Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TER | TGTX | |
|---|---|---|
Market Cap | $59.99B | $8.36B |
Sector | Technology | Health |
52-Week High | $483.84 | $59.06 |
52-Week Low | $112.24 | $26.94 |
Enterprise Value | $59.73B | $8.57B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $372.06, up 4.21% in the last session, with a bullish technical signal and strong institutional interest. The stock shows robust fundamentals, including a 59.24% gross margin and consistent earnings beats, with Q3 2026 EPS expected at $2.03. Recent news highlights AI-driven demand for UltraFLEXplus systems, positioning TER for growth in semiconductor testing.
Outlook is positive with a $474.78 analyst price target implying 28% upside, supported by AI and data center expansion. Risks include reliance on tech cycles and competitive pressures from KLA and Cohu. Cash flow trends show improvement, with net cash flow projected to turn positive in 2026.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
